NEW YORK – Aytu BioScience said on Thursday it has reached a definitive deal with Biolidics to exclusively distribute that firm's coronavirus serology test in the US.
Under the terms of the deal, Englewood, California-based Aytu has committed to purchasing at least 1.25 million of Biolidics' COVID-19 IgG/IgM Rapid Tests within the first three months of the deal, including 500,000 tests in the first business day after the signing of the agreement.
Further details were not disclosed.